Close

Intra-Cellular Therapies (ITCI) Prices Public Offering of Common Stock Apr 17, 2024 08:59PM
Intra-Cellular Therapies Prices Public Offering of Common Stock Apr 17, 2024 08:46PM
Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference Apr 11, 2023 08:00AM
Needham & Company Reiterates Buy Rating, $65 Price Target on Intra-Cellular Therapies (ITCI) Apr 13, 2022 05:47AM
Intra-Cellular Therapies to Present at the 21st Annual Needham Virtual Healthcare Conference Apr 5, 2022 08:00AM


Mar 29, 2022 06:24AM Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy with $65 PT, Sees Caplyta's Growth Accelerating & Potentially Beating Expectations
Mar 1, 2022 08:22AM Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy, Anticipates Uptick Following Earnings
Feb 25, 2022 07:00AM Intra-Cellular Therapies (ITCI) PT Raised to $65 at Needham & Company
Jan 7, 2022 04:01PM Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jan 5, 2022 06:04AM Intra-Cellular Therapies (ITCI) Prices 9.52M Share Offering at $42/sh
Jan 4, 2022 10:05PM Intra-Cellular Therapies Prices Public Offering of Common Stock
Dec 20, 2021 08:58AM Intra-Cellular Therapies (ITCI) PT Raised to $59 at Needham & Company; Sees >$800M in Caplyta Sales by 2026
Dec 6, 2021 06:41AM Needham & Company Previews Intra-Cellular Therapies (ITCI) Dec. 17th PDUFA for Caplyta
Sep 22, 2021 04:12PM Needham & Company Starts Intra-Cellular Therapies (ITCI) at Buy
Apr 4, 2016 08:00AM Intra-Cellular Therapies to Present at the 15th Annual Needham Healthcare Conference